Komori, Azusa
Otsu, Satoshi
Shimokawa, Mototsugu
Otsuka, Taiga
Koga, Futa
Ueda, Yujiro
Nakazawa, Junichi
Arima, Shiho
Fukahori, Masaru
Okabe, Yoshinobu
Makiyama, Akitaka
Taguchi, Hiroki
Honda, Takuya
Shibuki, Taro
Nio, Kenta
Ide, Yasushi
Ureshino, Norio
Mizuta, Toshihiko
Shirakawa, Tsuyoshi http://orcid.org/0000-0002-9317-8216
Mitsugi, Kenji
Article History
Received: 27 October 2022
Accepted: 5 May 2023
First Online: 20 May 2023
Declarations
:
: T.O. received grant from Chugai; T.S. received consulting fees from Taiho Pharmaceutical, Chugai, and Takeda; M.S. received personal fee from Sysmex Corporation; Y.K. received personal fee from Taiho Pharmaceutical; S.A. received personal fees from Taiho Pharmaceutical, Novartis Pharma, Chugai, Bristol-Myers Squibb, Daiichi-Sankyo, and AstraZeneca; A.M. received personal fees from Eli Lilly, Chugai, and Takeda. The remaining authors have no competing interests or financial disclosures to declare.
: This study was approved by the institutional review board or ethics committee of each participating institution prior to the study and conducted according to the Declaration of Helsinki.
: The requirement for consent to participate was waived because of the retrospective design of this study.
: The requirement for consent for publication was waived because of the retrospective design of this study.